Ovarian Rejuvenation Through Platelet-Rich Autologous Plasma (PRP)—a Chance to Have a Baby Without Donor Eggs, Improving the Life Quality of Women Suffering from Early Menopause Without Synthetic Hormonal Treatment

Petryk, Nataliia; Petryk, Mykhailo

doi:10.1007/s43032-020-00266-8

Cited by 35 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No RCT and the total number of patients in all studies is small. Ovarian reserve markers (increase in serum AMH or antral follicle count or decrease in serum FSH) were the outcome in all studies with a beneficial effect in all except Singh et al 2020 [8,9] who found no benefit. LBR was not determined in all studies.…”

Section: Discussionmentioning

confidence: 96%

“…LBR was not determined in all studies. Pregnancy rate was determined in Petryek et al [8] and Mello et al [10] studies, with significant improvement, but the number of patients was small, 38 patients and 46 patients, respectively. Therefore, intraovarian PRP for improvement of ovarian reserve cannot be recommended due to the absence of robust evidence and well-designed, large RCTS are required to confirm its efficacy and safety.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intraovarian platelet-rich plasma: current status

Elnashar

2021

Middle East Fertil Soc J

View full text Add to dashboard Cite

Background The successful use of PRP in regenerative medicine has led investigators to study its effect in the treatment of conditions like decreased ovarian reserve, poor responders, and premature ovarian insufficiency. Objective To review the uses of intraovarian PRP in reproductive medicine. Methods A literature search for English articles related to the uses of intraovarian PRP in reproductive medicine, including articles published in PubMed, from 2000 to April 2021. Results Seventeen studies: No RCT. Studies were classified according to indication. (1) For diminished ovarian reserve: 6 studies including 369 patients. (2). For poor responders: 3 case series studies including 41 patients with an improvement in ovarian response. (3) For premature ovarian insufficiency: 8 studies including 373 patients. Ovarian reserve markers were the outcome of all studies with conflicting results. LBR was not determined in the majority of studies. Conclusion Intraovarian PRP for diminished ovarian reserve, poor ovarian response, or POI is still experimental. Well-designed, large RCTS to confirm its efficacy and safety are required.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Intraovarian platelet-rich plasma: current status

Elnashar

2021

Middle East Fertil Soc J

View full text Add to dashboard Cite

show abstract

“…The use of PRP injections is effective and safe [ 7 ], and many studies pointed at the efficacy of using PRP in ovarian rejuvenation, where it successfully activated the follicles [26 , 27] . Other studies reported the benefit of directly injecting the ovaries with PRP through laparoscopically assisted technique [27 , 28] . In our case, we used a similar technique, where we inject the ovaries directly with the PRP through laparoscopy.…”

Section: Discussionmentioning

confidence: 99%

A new approach of using platelet-rich autologous plasma to increase the ovarian reservoir in a Syrian patient with ovarian insufficiency: A case report

Sabouni

Tarrab

kalaji

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Introduction The prevalence of Primary ovarian insufficiency (POI) is estimated to be 1–2%, resulting from many causes, including, iatrogenic causes which are becoming more common. There is no precise treatment to restore fertility in POI patients. However, new treatments -such as ovarian rejuvenation using platelet-rich autologous plasma (PRP)- are being tested and have shown promising results. We report using a new PRP injection protocol to manage a Syrian patient with ovarian insufficiency. Case presentation A 35-year-old woman with five years of primary infertility presented with decreased anti-mullerian hormone (AMH) after she underwent a laparoscopy one year ago. Where the AMH dropped from 1.07 to 0.39 ng/mL after it. She underwent an ovarian rejuvenation using PRP. Half mL of PRP was injected into every ovary, 2 mL were injected into the cervix, 7 mL intra-uterus, and 7 mL were injected intramuscularly to the patient's legs. Fifteen days following the operation, the patient's new AMH level was 0.94 ng/mL. The patient was placed on ovarian stimulation, and five days later the ultrasonography showed the development of six follicles in each ovary. Discussion Managing POI using ovarian rejuvenation is the best alternative treatment; When the donor eggs programs are not acceptable. The use of PRP in ovarian rejuvenation has been reported to be effective. Conclusion The use of PRP was beneficial in restoring fertility in a Syrian patient with ovarian insufficiency. Furthermore, the new PRP injection protocol was successful. However, more studies are needed to confirm this result.

show abstract

“…Success with OPRP has showcased its role in ovarian reserve upticks, over months or weeks, to optimize response to gonadotropin treatments for IVF. When this enables unassisted pregnancy (Sfakianoudis et al, 2020;Petryk & Petryk, 2020;Sills et al, 2020b), the investment in OPRP is recompensed by obviating costs of IVF. Quality-of-life gains or menopause reversal after OPRP while awaiting IVF, although welcome and never trivial, are best marked as incidental objectives.…”

Section: Discussionmentioning

confidence: 99%

Preliminary Cost Variance Modeling to Compare Autologous Intraovarian Platelet-Rich Plasma vs. Standard Hormone Replacement Therapy for Menopause Management

Sills¹,

Sl²

2021

Preprint

View full text Add to dashboard Cite

Background: Menopause symptoms and hormone replacement therapy (HRT) are among the most common reasons patients seek gynecological advice. Although at least half of all women in developed countries will take HRT during their lifetime, the treatment is not without risk and guidance on HRT is mixed. Greater awareness of negative HRT health effects from extended use has piqued interest in ‘safer options’. Menopause reversal with autologous ovarian platelet-rich plasma (OPRP) has brought this restorative approach forward for consideration, but appropriateness and cost-effectiveness require examination. Methods: HRT and OPRP data from USA were projected to compare cumulative 1yr patient costs using stochastic Monte Carlo modeling. Results: Mean±SD cost-to-patient for HRT including initial consult plus pharmacy refills was estimated at about $576±246/yr. While OPRP included no pharmacy component, an estimated 4 visits over 1yr for OPRP maintenance entailed ultrasound, phlebotomy/sample processing, surgery equipment, and incubation/laboratory expense, yielding mean±SD cost for OPRP at $8,710±4,911/yr (p<0.0001 vs. HRT, by t-test). Upper-bound estimates for annual HRT and OPRP costs were $1,341 and $22,232, respectively. Conclusions: While HRT and OPRP may have similar efficacy and safety for menopause therapy, they diverge sharply in cost-effectiveness. Most patients would likely find OPRP too complex, invasive, and expensive to be competitive vs. HRT. Although OPRP is an interesting and cautiously useful technique for selected menopause patients reluctant to use HRT, repurposing this infertility treatment for wider use appears inefficient compared to standard HRT currently available.

show abstract

Ovarian Rejuvenation Through Platelet-Rich Autologous Plasma (PRP)—a Chance to Have a Baby Without Donor Eggs, Improving the Life Quality of Women Suffering from Early Menopause Without Synthetic Hormonal Treatment

Cited by 35 publications

References 18 publications

Intraovarian platelet-rich plasma: current status

Intraovarian platelet-rich plasma: current status

A new approach of using platelet-rich autologous plasma to increase the ovarian reservoir in a Syrian patient with ovarian insufficiency: A case report

Preliminary Cost Variance Modeling to Compare Autologous Intraovarian Platelet-Rich Plasma vs. Standard Hormone Replacement Therapy for Menopause Management

Contact Info

Product

Resources

About